From: Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer
Group | Chemotherapy | Number | Overall survival rate OAS | Log-Rank | ||
---|---|---|---|---|---|---|
Total | Events | 5 years (%) | Median OAS (m) | P-value | ||
All patients (deceased within 30 days excluded) | + CTX | 79 | 14 | 81.7 | − | <0.001 |
−CTX | 161 | 56 | 51.7 | 63.3 | ||
Deceased within 60 days excluded | + CTX | 79 | 14 | 81.7 | − | 0.002 |
−CTX | 156 | 51 | 53.7 | 79.3 | ||
Deceased within 90 days excluded | + CTX | 79 | 14 | 81.7 | 95.5 | 0.006 |
−CTX | 152 | 47 | 55.4 | 79.3 | ||
Age at diagnosis < 60 years | + CTX | 25 | 5 | 90.9 | − | |
−CTX | 24 | 4 | 70.0 | − | 0.726 | |
Age at diagnosis 60 − 69 years | + CTX | 28 | 4 | 77.8 | − | 0,011 |
−CTX | 61 | 25 | 44.9 | 53.5 | ||
Age at diagnosis 70–79 years | + CTX | 26 | 5 | 77.0 | – | 0.064 |
−CTX | 76 | 27 | 52.0 | 63.6 | ||
Tumor grading G2 | + CTX | 56 | 8 | 87.0 | − | 0.009 |
−CTX | 125 | 39 | 60.0 | 89.0 | ||
Tumor grading G3 | + CTX | 23 | 6 | 68.9 | 95.5 | 0.014 |
−CTX | 36 | 17 | 23.4 | 42.9 |